Business
Dr. J. Jacques Carter Joins OncBioMune Pharmaceuticals Scientific Advisory Board
Dr. J. Jacques Carter Joins OncBioMune Pharmaceuticals Scientific Advisory Board.
About this update from Theralink Technologies Inc.
[{"type":"text","content":"\nDr. J. Jacques Carter Joins OncBioMune Pharmaceuticals Scientific Advisory Board \n\nDr. J. Jacques Carter Joins OncBioMune Pharmaceuticals Scientific Advisory Board\n\n\n BATON ROUGE, LA--(Marketwired - March 22, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) (\"OncBioMune\" or the \"Company\"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to announce the appointment of Dr. J. Jacques Carter to the Company's Scientific Advisory Board. Dr. Carter currently serves as a physician at the Beth Israel Deaconess Medical Center in Boston, MA and is an assistant professor at Harvard Medical School. From 2005 to 2014, he also served as the Medical Director of the Prostate Cancer Screening and Education Program at the Dana-Farber Cancer Institute.\"We're thrilled to welcome Dr. Carter to our Scientific Advisory Board,\" commented Dr. Jonathan Head, Chief Executive Officer at OncBioMune. \"As a highly respected physician and educator, Dr. Carter brings years of highly relevant experience and adds another well informed perspective to our team. His knowledge and expertise in the field of prostate cancer is synergistic and will prove invaluable with our clinical development of ProscaVax.\"\"I welcome this opportunity to work more closely with Dr. Head and his team at OncBioMune on all of their cancer therapies, particularly the novel vaccine ProscaVax,\" said Dr. Carter. \"Throughout my years of work in the prostate cancer space, I am poignantly aware of how important it is to diagnose and treat the disease as early as possible and equally aware of toxicity and morbidity issues related to all prostate cancer treatments. Moreover, there is an unfortunate dearth of safe, efficacious treatments for patients at disease presentation. I greatly look forward to lending my experience and knowledge throughout the clinical process in an effort to bring a new therapy to market for all of the patients so desperately in need.\"Dr. Carter completed his residency training in Internal Medicine at Beth Israel Deaconess Medical Center in Boston, followed by a graduate program at the Harvard School of Public Health, where he received his MPH degree. He then completed a clinical fellowship in Primary Care Medicine at the Mass...